

WP5: Early detection, prevention and health promotion

Ms Satu Lipponen, WP5 leader, Cancer Society of Finland/ THL Second iPAAC JA Stakeholder Forum meeting, Brussels, 10 December 2019






Strategies for early detection of cancer

Effective solutions for population-based screening programmes

Cancer prevention & health promotion, HiAP: implementation of the European Code Against Cancer

Inequality a **cross-cutting** theme integrated in above mentioned tasks



MAIN OBJECTIVES OF WP5



- identify barriers to early detection and its management March 2019 survey M5.1
- strengthen quality aspects of population-based screening policies by developing decision making tools, including cost-effectiveness and analysis of harms and benefits
- investigate the possibilities and barriers of risk-stratified protocols within the frameworks of population-based cancer screening programmes – report M5.2.
- monitor and review European Code Against Cancer in the long-term perspective focussing on policy tools and guidance given to the general public - M5.3
- analyse how governmental policies adopted in Member States foster successful cancer prevention, emphasizing cancer-site specific determinants in each country
- review and plan better endorsement of recommendations within the European Code Against Cancer and to increase aspects of health for all and in every policy for local, regional and EU-level – M5.3.
- Roadmap (Deliverable)



Institute of Oncology Ljubljana, SLOVENIA National Center of Public Health and Analyses, BULGARIA **Croatian Institute of Public Health, CROATIA** Institute of Health Information and Statistics of the Czech Republic, CZECH Finnish institute for health and welfare+ Cancer Society of Finland, FINLAND French National Cancer Institute, FRANCE Federal Ministry of Health + German Cancer Society, GERMANY Uniklinik Köln **Deutsches Krebsforschungszentrum Canccer Information Service National Institute of Oncology, HUNGARY** National Institute of Public Health, ITALY **Veneto Institute of Oncology Cancer Research and Prevention Institute** Ministry of Health of the Republic of Lithuania, LITHUANIA Ministry for Health, MALTA National Institute for Public Health and the Environment, NETHERLANDS **Cancer Registry of Norway, NORWAY** National Institute of Public Health Romania, ROMANIA Institute of Public Health of Serbia "Dr Milan Jovanović Batut", SERBIA Catalonia Institute of Oncology + The Foundation for the Promotion of Health and Biomedical Research of Valencia Region, FISABIO, SPAIN **Department of Health from the Region of Murcia** Spanish network of Cancer registries, Instituto Carlos III Osakidetza (Servicio Vasco de Salud/Basque Health System) **Association of European Cancer Leagues, BELGIUM International Agency for Research on Cancer, FRANCE**

+ collaborating partners

COLLABORATING PARTNERS WP5



ORGANIZATION

National Association of Statutory Health Insurance Physicians (Germany)

European Oncology Nursing Society EONS

European Association of Urology EAU

University College Dublin UCD (Ireland)

EuropaColon

COCIR /Siemens Healthineers

European Society of Radiology ESR

United European Gastroenterology UEG

funding4health


Central European Cooperative Oncology Group CECOG

Kishor Hadkhale (Tampere University) (Finland)



IPAAC WP5 TIMELINE OF KEY ACTIVITIES





BARRIERS: IPAAC SURVEY



Barriers in 3 levels: population, health services and individual domains

- Awareness on early signs of cancer still inadequate
- Lack on evidence in many cancer types (skin, oral, breast and prostate cancers and other cancers)
- Focus on programmatic health services on early diagnosis
- Inequalities: awareness, health literacy and financial constraints
- Answers from over 30 countries, 153 completed survey

 From iPAAC Conference 5.1. report Insight and effeticeveness of early diagnosis, November 2019 (unpublished)



BARRIERS BY IMPORTANCE



Barrier	Oral cancer	Skin cancer	Prostate cancer	Breast cancer	Other cancers	Overall
Lack of awareness	<mark>72</mark>	<mark>73</mark>	65	<mark>69</mark>	69	70
Lack of evidence	65	70	<mark>68</mark>	67	<mark>74</mark>	69
Poor organization of patient pathway	66	66	66	<mark>68</mark>	62	66
Patient-level financial constraints	<mark>74</mark>	48	52	59	61	59
Limited access to primary care	<mark>68</mark>	54	47	62	54	57
Cancer stigma	63	49	58	54	55	56



IPAAC WP5 TASK 5.2. CANCER SCREENING





Report on innovations in population-based cancer screening programmes, including harms and benefits from risk-stratified screening & new evidence evolving from the field of genomics (September 2019)



Quality criteria in cancer screening for policy-makers in easy to share and interactive infographich form

Decision making tools, including cost-effectiveness



Innovations in popbased screening: background material Review of background material

Co-creation elements of the conference

Technical meeting & conference Helsinki 4-5/12/19

Report on screening (July2020) Roadmap (March 2021)



TASK 5.2. CANCER SCREENING





New openings of cancer screening in Europe

Welcome to the 2nd WP5 iPAAC conference! Hosted by: The Finnish Institute for Health and Welfare (THL) and the Cancer Society of Finland
















Incidence and mortality from cervical cancer in Finland 1953-2017





RISK STRATIFICATION AND CANCER SCREENING



Main focus: means and opportunities to optimize the balances of harms and benefits of population-based screening programmes – screening asymptomatic, healthy people for early detection

What about those in a high risk?

- Risk stratification within extisting programmes is selective screening within a population-based approach
- EU Council has recommended screening for breast, cervical and colorectal cancers; of these for instance cervical cancer programme faces changes with HPV vaccinated cohorts
- Screening programmes are complex public health measures, not just taking a test
- Surveillance programmes defined as close and continuous observation of high-risk groups identified largely from clinical environment



WORK FROM EARLIER JA:S



- European Partnership for Action Against Cancer (EPAAC) 2009– 2013 – programmatic health care services for the task 5.1., prevention
- Cancer Control Joint Action (CANCON) 2014-2017
- CANCON Chapter Screening from the European Guide on Quality Improvement in Comprehensive Cancer Control
- CANCON Policy paper Tackling Social Inequalities in Cancer Prevention and Control for the European Population
- Other Joint Actions







CONTEST OF BEST PRACTICES TACKLING SOCIAL INEQUALITIES IN CANCER PREVENTION





Aims:

- ✓ Identify and compile European experiences allowing to reduce s
- \checkmark **Disseminate** these experiences in order to promote the exchang
- Ensure continuity of previous work (CanCon recommendations innovative approach.




Aligned with **DG Sante's priority** on "identifying, disseminating and transferring best practices in order to make progress in health promotion and in non-communicable disease prevention in Europe".





Results






















Organisation	Objective	Type of intervention
Flemish Centre for Cancer Detection (Belgium)	Improve cancer screening information for people with functional diversities.	Improvement of digital accessibility, constructing a Perceivable, Operable, Understandable and Robust Website.
NHS England/Improvement (United Kingdom)	Reduce age inequalities in cervical screening uptake	Reinforcing invitation strategy by sending text reminders (in addition to invitation letter).
English NHS Bowel Cancer Screening Programme (United Kingdom)	Decrease SES gradient in bowel cancer screening uptake	Sending Enhanced Reminder letters aimed specifically at individuals who had not responded to the initial invitation.
National Institute of Public Health (Slovenia)	Increase participation of people with lower level of education, men, and communities with the lowest response.	Extensive information and awareness campaigns (TV, radio, local exhibitions and fairs, SVIT embassadors, information points at primary care centers).
Public Health Local Centre (Spain)	Promote a favourable attitude of deprived population towards cancer (primary and secondary) prevention.	Empowerment and Peer-education on cancer prevention by community health agents.





UNDERSTANDING COMPLEXITY



- Basic principles on disease/condition and testing/intervention normally high-level but programme/system principles much less developed and depending context
- Screening decisions highly complex/ no easy yes and no answers – decisions need many sort of expertise
- All EU council recommended cancer screening programmes breast, cervical and colorectal – need boosting
- Cancer screening has improved in 15 years but there is room for making screening programmers more effective
- Updates on lung, prostate and ovarian cancer, diversity of opinions



IPAAC WP5 TASK 5.3. CANCER PREVENTION





European Code Against Cancer. further development (policy), explanations of the code (JA+IARC)



Plan for monitoring and developing ECAC implementation, including follow-up (JA+IARC) / technical report in February 2020



Health in all policies: taxation, education, legislation, environment etc.





Drafting comprehensive strategies

Governmental perspective

Conference co-creation elements



Monitoring ECAC report (Sept 2020)
Conference report (Nov2020)



EUROPEAN CODE AGAINST CANCER



- 12 strategies to prevent cancer burden
- There is evidence and need to improve prevention
- Not only in health domain but across policies (Health in all policies principle)
- Tobacco excise taxes one example: prevention works!
- IARC as subcontractor, technical report in February 2020
- Best practices competition results on prevention forthcoming
- Most important goal: reduce incidence and mortality in Europe

MEETINGS AND SAVE THE DATE FOR TASK 5.3.



- Task 5.1. Budapest conference 20.5.2019 over 70 registered
- Task 5.2. Helsinki conference 5.12. nearly 80 registered
- Save the date: 29.4. 2020 open conference/ venue IARC HQ, Lyon France

THANK YOU! (BUDAPEST WP5 MEETING IN MAY 2019)





